UNICA IRIS Institutional Research Information System

BARCELLONA, DORIS
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 123.402
NA - Nord America 7.528
AS - Asia 3.817
SA - Sud America 752
AF - Africa 180
OC - Oceania 61
Continente sconosciuto - Info sul continente non disponibili 5
Totale 135.745
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 121.292
US - Stati Uniti d'America 7.360
SG - Singapore 1.437
CN - Cina 1.075
BR - Brasile 574
SE - Svezia 441
VN - Vietnam 416
GB - Regno Unito 319
DE - Germania 305
UA - Ucraina 259
FI - Finlandia 197
HK - Hong Kong 181
FR - Francia 163
IN - India 124
CA - Canada 89
NL - Olanda 85
BD - Bangladesh 64
KR - Corea 64
AR - Argentina 61
JP - Giappone 53
MX - Messico 53
IQ - Iraq 52
AU - Australia 50
TR - Turchia 50
ZA - Sudafrica 49
AT - Austria 43
ES - Italia 43
IE - Irlanda 43
PK - Pakistan 38
PL - Polonia 37
IR - Iran 36
EG - Egitto 33
ID - Indonesia 33
MA - Marocco 31
CO - Colombia 30
RU - Federazione Russa 29
EC - Ecuador 24
MY - Malesia 21
UZ - Uzbekistan 21
BE - Belgio 20
DK - Danimarca 19
PH - Filippine 19
SA - Arabia Saudita 18
CH - Svizzera 16
TW - Taiwan 16
KE - Kenya 15
PY - Paraguay 15
CL - Cile 13
JO - Giordania 13
TN - Tunisia 13
ET - Etiopia 12
LT - Lituania 12
PE - Perù 12
CZ - Repubblica Ceca 11
NP - Nepal 11
NZ - Nuova Zelanda 11
BG - Bulgaria 10
AE - Emirati Arabi Uniti 9
VE - Venezuela 9
HU - Ungheria 8
IL - Israele 8
SD - Sudan 8
DZ - Algeria 7
RO - Romania 7
TH - Thailandia 7
UY - Uruguay 6
BH - Bahrain 5
CY - Cipro 5
KZ - Kazakistan 5
NO - Norvegia 5
PT - Portogallo 5
AZ - Azerbaigian 4
BA - Bosnia-Erzegovina 4
BY - Bielorussia 4
CR - Costa Rica 4
GE - Georgia 4
GY - Guiana 4
KG - Kirghizistan 4
LB - Libano 4
MU - Mauritius 4
OM - Oman 4
PA - Panama 4
PR - Porto Rico 4
EU - Europa 3
KW - Kuwait 3
LK - Sri Lanka 3
LU - Lussemburgo 3
MT - Malta 3
RS - Serbia 3
SK - Slovacchia (Repubblica Slovacca) 3
SY - Repubblica araba siriana 3
AL - Albania 2
BO - Bolivia 2
CI - Costa d'Avorio 2
DM - Dominica 2
DO - Repubblica Dominicana 2
EE - Estonia 2
GF - Guiana Francese 2
GR - Grecia 2
HR - Croazia 2
Totale 135.715
Salva come PNG Salva come JPEG
Città #
Cagliari 115.271
Uta 5.371
Fairfield 765
Ashburn 689
Singapore 673
Woodbridge 526
Dallas 497
Houston 402
San Jose 380
Boardman 313
Seattle 306
Nyköping 296
Chandler 293
Wilmington 287
Cambridge 259
Ann Arbor 246
Beijing 227
Hong Kong 156
Los Angeles 153
Helsinki 140
Jacksonville 133
Council Bluffs 123
Ho Chi Minh City 120
The Dalles 120
Santa Clara 110
New York 103
Shanghai 102
Lauterbourg 96
Dearborn 93
Boston 83
Hanoi 79
Rome 69
Buffalo 63
Dong Ket 58
San Diego 56
São Paulo 56
Nanjing 52
Munich 51
Hefei 48
Seoul 47
Milan 42
Redwood City 42
Frankfurt am Main 39
Nuremberg 38
Redondo Beach 38
Chicago 37
Guangzhou 37
Dublin 31
Tokyo 31
Toronto 29
Vienna 28
London 27
Warsaw 27
Johannesburg 25
Shenyang 25
Stockholm 23
Brandenburg 22
Orem 22
Amsterdam 21
Atlanta 20
Tashkent 20
Tianjin 20
Phoenix 19
Sydney 19
Baghdad 18
Chennai 18
Hebei 18
Rio de Janeiro 18
Selargius 18
Ankara 17
Brussels 17
Denver 17
Haiphong 17
Turku 17
Bogotá 16
Brooklyn 16
Changsha 16
College Station 16
Lahore 16
Mexico City 16
Nanchang 16
Manchester 15
Redmond 15
Central 14
Jiaxing 14
Nairobi 14
Salt Lake City 14
Sassari 14
Montreal 13
Mountain View 13
Amman 12
Mumbai 12
Baoding 11
Biên Hòa 11
Cape Town 11
Da Nang 11
Delhi 11
Norwalk 11
Orange 11
Poplar 11
Totale 130.119
Salva come PNG Salva come JPEG
Nome #
Abnormal lipid accumulation and cluster formation of naive peripheral blood mononuclear cells: a useful tool for early detection of central nervous system damage in elderly 2.875
Heterogeneity of Antiphospholipid Syndrome (APS) as Characterized by Brain Perfusion Techniques. Towards New Ways of Syndrome Characterization 2.793
The venous thromboembolic risk and the clot wave analysis: a useful relationship? 2.768
Prophylaxis of peripartum haemorrhage using recombinant factor VIIa (rfVIIa) in pregnant women with congenital factor VII deficiency: A case report and literature review 2.751
Myocardial infarction and Antiphospholipid Syndrome: A first study on finger PPG waveforms effects 2.572
Dabigatran overdose: a case report of acute hepatitis. Extracorporeal treatment. 2.564
Olanzapine-associated portal and superior mesenteric vein thrombosis 2.517
Are prothrombin time and clot waveform analysis useful in detecting a bleeding risk in liver cirrhosis? 2.434
Telemedicine can improve the quality of oral anticoagulation using portable devices and self-testing at home 2.310
Clot wave analysis and thromboembolic score in liver cirrhosis: two opposing phenomena 2.297
Empathy and the Educational Approach to Patients With Atrial Fibrillation Treated With Direct Oral Anticoagulants 2.179
Underuse of anticoagulant therapy in hospitalized older patients: comment on the article of Wojszel et al 2.166
Management of Patients Taking Oral Anticoagulants Who Need Urgent Surgery for Hip Fracture 2.155
Multiple specialized stem cell niches characterize hematopoiesis in the human fetal liver 2.083
Pulmonary Thrombosis: A Clinical Pathological Entity Distinct from Pulmonary Embolism? 2.071
Clot Waveform Analysis: From Hypercoagulability to Hypocoagulability - A Review 2.011
A Sardinian Family with Factor XI Deficiency 1.997
Ultrastructural findings of lung injury due to Vaccine-induced Immune Thrombotic Thrombocytopenia (VITT) following COVID-19 vaccination: a scanning electron microscopic study 1.949
A “Catastrophic” Heparin-Induced Thrombocytopenia 1.884
Vaccine-induced severe thrombotic thrombocytopenia following COVID-19 vaccination: A report of an autoptic case and review of the literature 1.878
Points of Care Testing International Normalized Ratio: Are They Useful for Monitoring Vitamin K Antagonists in a Thrombosis Center? 1.809
The hemostatic system. 1st Part 1.806
Molecular pathways triggered by COVID-19 in different organs: ACE2 receptor-expressing cells under attack? A review 1.743
Point-of-care testing INR: an overview 1.681
Has time come for the use of direct oral anticoagulants in the extended prophylaxis of venous thromboembolism in acutely ill medical patients? No 1.661
Pulmonary thrombosis in 2019-nCoV pneumonia? 1.654
Risk of reoperation in bioprosthetic valve patients with indication for longterm anticoagulation. Results from the observational retrospective multicentre PLECTRUM study 1.649
Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome 1.624
Patients' adherence to oral anticoagulants therapy: Comparison between vitamin K antagonists and direct oral anticoagulants 1.604
Mechanical prosthetic heart valves: Quality of anticoagulation and thromboembolic risk. The observational multicenter PLECTRUM study 1.574
Direct oral anticoagulants: what can we learn? 1.568
Comparison of prothrombin time INR and clot waveform analysis performed with 129-mmol/L and 105-mmol/L citrate tubes 1.564
Fatal Cytopenia Induced by Low-Dose Methotrexate in Elderly With Rheumatoid Arthritis. Identification of Risk Factors 1.512
The criteria of the Italian Federation of Thrombosis Centres on DOACs: a ‘‘real world’’ application in nonvalvular atrial fibrillation patients already on Vitamin K Antagonist 1.481
Allele 4G of gene PAI-I associated with prothrombin mutation G20210A increases the risk for venous thrombosis 1.454
Thrombosis centres and AVKs monitoring in COVID-19 pandemic 1.445
Ultrasound-guided fine-needle aspiration biopsy of thyroid nodules in patients on oral anticoagulants 1.392
Fondaparinux: Should It Be Studied in Patients with COVID-19 Disease? 1.366
Direct inhibitors of thrombin and factor Xa: the importance of laboratory skills 1.348
A guide to oral anticoagulation 1.326
Findings from a multicentre, observational study on reproductive outcomes in women with unexplained recurrent pregnancy loss: the OTTILIA registry 1.311
Portable coagulometer for vitamin K-antagonist monitoring: the patients’ point of view 1.307
The Repeatable Battery for the Assessment of Neuropsychological Status as a screening strategy for HIV-Associated Neurocognitive Disorders 1.296
Hyperhomocysteinemia: could the post-methionine oral loading test sometimes be avoided? 1.285
The Italian START-Register on anticoagulation with focus on atrial fibrillation 1.266
Antiphospholipid syndrome patients: The performance of Coagucheck XS in the monitoring of Vitamin K-Antagonists 1.251
Heparins and 2019-nCoV infection: a narrative review 1.243
A ‘‘two-step’’ educational approach for patients taking oral anticoagulants does not improve therapy control 1.227
Thyroid disorders and hypocoagulability 1.183
The predictive ability of bleeding risk stratification models in very old patients on vitaminK antagonist treatment for venous thromboembolism: results of the prospective collaborative EPICA study 1.179
Clinical course of high-risk patients diagnosed with antiphospholipid syndrome 1.148
Vitamin K antagonists (coumarins), drugs used in the prevention and treatment of cardioembolism, deep vein thrombosis, and pulmonary embolism 1.129
High frequency of inadequate test requests for antiphospholipid antibodies in daily clinical practice 1.124
Anticoagulation resumption after intracranial hemorrhage in patients treated with VKA and DOACs 1.088
Liver changes in Wilson’s disease: The full spectrum. A report of 127 biopsies from 43 patients 1.086
Fetal programming of atherosclerosis: may the barker hypothesis explain the susceptibility of a subset of patients to develop stroke or cardiac infarct? 1.084
A routine silica-based activated partial thromboplastin time (Hemosil aPTT-SP (TM)) mostly excludes the presence of lupus anticoagulant 1.076
Association of Antiplatelet and Anticoagulant Treatment in Patients with Mechanical Prosthetic Heart Valves. Data from the Observational Multicentre PLECTRUM Study 1.076
Rheumatoid arthritis and thrombosis 1.073
Prevalence and significance of anti-prothrombin (aPT) antibodies in patients with Lupus Anticoagulant (LA) 1.065
Fetal programming of COVID-19: May the barker hypothesis explain the susceptibility of a subset of young adults to develop severe disease? 1.010
Infectious agents including COVID-19 and the involvement of blood coagulation and fibrinolysis. A narrative review 1.002
Point-of-care (POCT) prothrombin time monitors: is a periodical control of their performance useful? 1.001
Clot characterization by multidisciplinary approach: biochemical and imaging parameters in a hypocoagulative setting. A pilot study 988
Position paper on the safety/efficacy profile of Direct Oral Anticoagulants in patients with Chronic Kidney Disease: Consensus document of Società Italiana di Nefrologia (SIN), Federazione Centri per la diagnosi della trombosi e la Sorveglianza delle terapie Antitrombotiche (FCSA) and Società Italiana per lo Studio dell’Emostasi e della Trombosi (SISET) 936
Aortic vulnerability to COVID-19: Is the microvasculature of vasa vasorum a key factor? A case report and a review of the literature 883
Thrombotic sinusoiditis and local diffuse intrasinusoidal coagulation in the liver of subjects affected by COVID-19: The evidence from histology and scanning electron microscopy 880
Management of DOAC in patients undergoing planned surgery or invasive procedure: FCSA position paper 857
null 845
Managing anticoagulation in the COVID-19 era between lockdown and reopening phases 843
Scanning electron microscopy of lung disease due to COVID-19 – a case report and a review of the literature 836
The management of acute venous thromboembolism in clinical practice - study rationale and protocol of the European PREFER in VTE Registry 833
Chronic intravascular coagulation in liver cirrhosis predicts a high hemorrhagic risk 830
null 824
Trial of Rivaroxaban in AntiPhospholipid Syndrome (TRAPS): Two-year outcomes after the study closure 822
Chronic spontaneous urticaria: a low-grade disseminated intravascular coagulation only partially reversed by Omalizumab 821
null 789
Sex-based difference in anticoagulated patients with mechanical prosthetic heart valves and long-term mortality risk 786
Clinical history and gastrointestinal bleeding in patients taking oral anticoagulants 777
null 772
Position paper on the safety/efficacy profile of direct oral anticoagulants in patients with chronic kidney disease. Consensus document from the SIN, FCSA and SISET 741
Comparison of anticoagulation quality between acenocoumarol and warfarin in patients with mechanical prosthetic heart valves: Insights from the nationwide PLECTRUM study 741
Bleeding risk in very old patients on vitamin K antagonist treatment: results of a prospective collaborative study on elderly patients followed by Italian Centres for Anticoagulation 689
null 679
null 644
null 633
null 617
null 616
null 579
null 573
null 547
null 491
Over-anticoagulation by vitamin K antagonists and gender differences 470
Hormones and thrombosis: the dark side of the moon 453
Contraceptives and Thrombosis: An Intertwined Revolutionary Road 445
null 440
null 436
Performance and Interpretation of Clot Waveform Analysis 426
Why Does Rivaroxaban Not Work in Severe Mitral Stenosis? 410
Warfarin or acenocoumarol: which is better in the management of oral anticoagulants? 396
Totale 129.373
Salva come PNG Salva come JPEG
Categoria #
all - tutte 178.933
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 178.933
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20214.715 0 0 0 0 0 0 0 0 0 1.850 1.625 1.240
2021/20228.985 796 650 357 537 721 713 592 531 736 1.001 1.211 1.140
2022/202313.417 1.236 1.862 1.850 1.246 1.120 1.337 652 821 814 790 1.040 649
2023/202413.891 477 803 541 950 1.432 2.101 2.368 987 653 891 1.330 1.358
2024/202530.870 6.693 8.203 5.303 2.881 2.608 1.761 2.023 130 332 427 212 297
2025/20267.269 491 285 1.012 704 625 497 1.329 520 684 1.122 0 0
Totale 136.266